Non in Medical Technology
Navigation Links
Non in Medical Technology
Segment fails to mention ongoing FDA-approved HIFU clinical trials in the
United States and abundant clinical data on HIFU outcomes and experience
CHARLOTTE, N.C., June 27 /PRNewswire/ -- USHIFU, LLC, the exclusive
distributor of the minimally invasive Sonablate(R) 500 for prostate cancer
tre...
...vailable at: www.pnas.org/cgi/doi/10.1073/pnas.0405220101 . Accessed on 5 May 2009. Riely G. J. et al. "Clinical Course of Patients with non -Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib." Clin. Cancer Res, 12...
... heat within the prostate. This results in the focal destruction of prostatic tissue. High Intensity Focused Ultrasound does not use radiation and is non surgical. In a small U.S. safety trial, 91 percent of the participants treated in the study had a negative biopsy at six months. Some men with...
... North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (...
...throughout California. www.westly.org Global Health Research Foundation Global Health Research Foundation is a Los Altos, CA-based 501C non profit providing community-based, sustainable health methodologies and tools for use by local health workers worldwide. www.ghrf.org Health...
...nce of severe or fatal hemoptysis (internal bleeding in the lungs) to overall poor response. Current methods for differentiating squamous from non squamous non-small cell lung cancer lack standardization, are difficult to reproduce, and have low accuracy. Studies that reviewed the accuracy and re...
...ology media materials, visit www.gskcancermedia.com GSK Enquiries: Onsite Media enquiries: Greg Clarke - non US media only +1 610 405 0053 Ken Inchausti - US media only +1 267 809 7552 UK Media enquiries: Philip Thomso...
... was in patients given warfarin (7.8 percent, 10.6 percent and 3.2 percent, respectively). In contrast, the incidence of major and clinically relevant non major bleeding events with the 30 and 60 mg once-daily DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent, and 3.2 percen...
...ceftaroline, in North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (...
...w(TM) Squamous, Which Differentiates Squamous From non Squamous non Small Cell Lung Cancer, With Current Diagnostic Me...s, which differentiates squamous from non squamous non small cell lung cancer, with available immunohisto...
...RNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain. PF-4523655 (RTP801i-14), currently in Phase II clinical tr...
... demonstrated a half-life of approximately 26 days for IV administration. Valortim(R) has been tested in both the New Zealand White (NZW) rabbit and non human primate models to evaluate its efficacy in the post-exposure prophylaxis and therapeutic settings. In the post-exposure setting, Valortim(R) w...
...first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical...
...ecent public announcements by major HIV opinion leaders and pharmaceutical companies of their disappointing results despite significant investments in non productive vaccine strategies, attention is now beginning to refocus on the mucosa approach. Mymetics, with a robust IP portfolio and having originall...
...ime to symptom exacerbation than patients who received the reference dose and that the four-week 405 mg and the pooled two-week dosing regimens showed non inferiority when compared to oral olanzapine and to each other. About Olanzapine LAI Post-Injection Syndrome Analysis As with all medications, the...
...ment options are needed." About the Study To participate in the study, patients had to be at least 60 years of age or at least 18 years of age and non suitable for intensive chemotherapy combination treatment, with a WHO performance status 0 or 1. The EORTC's protocol called for a maximum of 6 treatm...
... Approximately 185,000 people are diagnosed with non Small Cell Lung Cancer each year in the United Sta...ompany's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Co...
...cluding Canada, Mexico, the Dominican Republic and the Bahamas, to make the non invasive therapy available. USHIFU is also funding FDA-approved clinical tr...0 different sites. About the Sonablate(R) 500 The Sonablate(R) 500 is a non invasive medical device that utilizes ultrasound energy to destroy tissue w...
...velop lung cancer diagnostic tests, specifically, through identifying unique microRNA signatures that may predict risk of recurrence in stage I and II non Small Cell Lung Cancer (NSCLC) patients, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securi...
...for Stage IV disease is six months. Treatment of melanoma depends on the stage of the disease with surgical resection being effective in less severe non metastatic forms of the disease. However, survival rates for later Stage III and IV patients are poor, reflecting the lack of any efficacious drugs fo...
... the identification and diagnosis of brain malignancies. 6. "MicroRNAs as a diagnostic tool for differentiating squamous cell lung cancer from other non small cell lung cancers" Lung cancer is the leading cause of cancer-related death among men and women. Of all lung cancer cases, 80% are non-small-cel...
...ies that are used to create its human and animal therapeutic agents. The most advanced human product candidate for Bioniche is Urocidin(TM) to treat non muscle-invasive bladder cancer. Urocidin(TM) entered Phase III clinical development in late 2006 after receiving Fast Track status from the U.S. Food ...
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
...ood glucose levels, increase the body's sensitivity to insulin, and reduce fat mass and body weight in animals. Isis partnered with non profit foundations to pursue new treatments for debilitating diseases, such as severe neurodegenerative diseases. Isis was awarded a grant from...Alfacell Provides Shareholder Update
... thought, consideration, and input from highly respected lung experts, we have decided our path moving forward would be to conduct a clinical trial in non small cell lung cancer (NSCLC) in patients who have become resistant to platinum therapy. Dr. David Sidransky (Alfacell Chairman of the Board) is spea......vailable at: www.pnas.org/cgi/doi/10.1073/pnas.0405220101 . Accessed on 5 May 2009. Riely G. J. et al. "Clinical Course of Patients with non -Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib." Clin. Cancer Res, 12...
AACR Data Highlights InNexus Preclinical Antibody Candidate
...XL(TM)), announced today that the company will be presenting new data on its lead preclinical candidate DXL625 (CD20) for the prospective treatment of non Hodgkin's Lymphoma (NHL) at the annual meeting of the American Association for Cancer Research (AACR), April 18-22, in Denver. "Preclinical data ...Major Restless Legs Study Completes Enrollment With Support From MediciGlobal
...o ensure that site staff could handle the workflow and no RLS patients were lost in the screening process. "The team approached this project in a non traditional way," says Moench. "The sponsor was open and willing to fresh ideas and marketing techniques, and clinical trial site enthusiastically emb...... heat within the prostate. This results in the focal destruction of prostatic tissue. High Intensity Focused Ultrasound does not use radiation and is non surgical. In a small U.S. safety trial, 91 percent of the participants treated in the study had a negative biopsy at six months. Some men with...
ExonHit Reports Proof-of-Concept in Breast Cancer Diagnostic Using its SpliceArray(TM) Platform
... About Institute Gustave Roussy The Institut Gustave Roussy (IGR, Villejuif, France), European leading Comprehensive Cancer Center, is a non profit academic entity belonging to the French public hospital service and that is authorized to receive donations and legacies. IGR is a center wholl...... North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (...
...throughout California. www.westly.org Global Health Research Foundation Global Health Research Foundation is a Los Altos, CA-based 501C non profit providing community-based, sustainable health methodologies and tools for use by local health workers worldwide. www.ghrf.org Health...
Pharmasset Reports Fiscal Year End 2008 Financial Results
...to 19% (3 of 16) in the control group. Further results in genotype 2 and 3, non responder patients treated with 1500mg BID generated RVR rate of 90% (18 of...FERRED RENT 79,793 204,256 non CURRENT PORTION OF CAPITAL LEASE OBLIGATION ......nce of severe or fatal hemoptysis (internal bleeding in the lungs) to overall poor response. Current methods for differentiating squamous from non squamous non-small cell lung cancer lack standardization, are difficult to reproduce, and have low accuracy. Studies that reviewed the accuracy and re...
...ology media materials, visit www.gskcancermedia.com GSK Enquiries: Onsite Media enquiries: Greg Clarke - non US media only +1 610 405 0053 Ken Inchausti - US media only +1 267 809 7552 UK Media enquiries: Philip Thomso...
... was in patients given warfarin (7.8 percent, 10.6 percent and 3.2 percent, respectively). In contrast, the incidence of major and clinically relevant non major bleeding events with the 30 and 60 mg once-daily DU-176b regimens was comparable to that with warfarin (3.0 percent, 3.8 percent, and 3.2 percen...
...ceftaroline, in North America. Novexel retains worldwide rights on the NXL104/ceftazidime combination. About NXL104 NXL104 is a novel injectable non beta lactam, beta-lactamase inhibitor, which is being developed to address the increasing problem of microbial resistance to beta lactam antibiotics (...
Tackling Atrial Fibrillation and Associated Cardiovascular Risk
... -- to better understand the impact of dronedarone on hospitalization of AF patients particularly on the number and duration of CV and non CV hospitalization nights -- An additional sub-analysis was also conducted to further explore dronedarone's rhythm and rate controlling properti......w(TM) Squamous, Which Differentiates Squamous From non Squamous non Small Cell Lung Cancer, With Current Diagnostic Me...s, which differentiates squamous from non squamous non small cell lung cancer, with available immunohisto...
...RNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain. PF-4523655 (RTP801i-14), currently in Phase II clinical tr...
... demonstrated a half-life of approximately 26 days for IV administration. Valortim(R) has been tested in both the New Zealand White (NZW) rabbit and non human primate models to evaluate its efficacy in the post-exposure prophylaxis and therapeutic settings. In the post-exposure setting, Valortim(R) w...
...first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical...
...ecent public announcements by major HIV opinion leaders and pharmaceutical companies of their disappointing results despite significant investments in non productive vaccine strategies, attention is now beginning to refocus on the mucosa approach. Mymetics, with a robust IP portfolio and having originall...
Rosetta Genomics Identifies Potential microRNA Biomarkers in Blood Serum
...first test based on the company's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Columbia University Medical......ime to symptom exacerbation than patients who received the reference dose and that the four-week 405 mg and the pooled two-week dosing regimens showed non inferiority when compared to oral olanzapine and to each other. About Olanzapine LAI Post-Injection Syndrome Analysis As with all medications, the...
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
... Total current liabilities 11,083,924 10,936,045 DEFERRED RENT 111,164 204,256 non CURRENT PORTION OF CAPITAL LEASE OBLIGATION - 41,641 DEFERRED REVENUE 4,333,257 5,726,131 LONG......ment options are needed." About the Study To participate in the study, patients had to be at least 60 years of age or at least 18 years of age and non suitable for intensive chemotherapy combination treatment, with a WHO performance status 0 or 1. The EORTC's protocol called for a maximum of 6 treatm...
Amicus Therapeutics Announces Second Quarter 2008 Financial Results
...$50 million. The Company also stated that it does not expect to raise cash from any equity financings in 2008. The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 and 3, and are primarily due to: -- Pre-tax stock compensation expense -- Pre-tax charges ...Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
...Inc. 14,304 23,952 Stockholders equity 60,696 75,991 Total liabilities, non controlling interest and stockholders' equity $122,279 $149,125 (1) Derived from audited consolidated financial statements at tha...Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
...cing hyaluronan (HA), consistent with the selective reduction of tumor interstitial fluid pressure (IFP). Treatment with PEGPH20 was well tolerated in non tumor-bearing mice without significant increases in neutropenia (depletion of neutrophils, a type of white blood cell) compared to chemotherapy alone....... Approximately 185,000 people are diagnosed with non Small Cell Lung Cancer each year in the United Sta...ompany's technology, differentiating squamous from non squamous non small cell lung cancer, is now approved through Co...
...cluding Canada, Mexico, the Dominican Republic and the Bahamas, to make the non invasive therapy available. USHIFU is also funding FDA-approved clinical tr...0 different sites. About the Sonablate(R) 500 The Sonablate(R) 500 is a non invasive medical device that utilizes ultrasound energy to destroy tissue w...
GeoVax Reports Progress on Its AIDS Vaccine Technology
...t SIV infection, conventional anti-viral drug therapy was given to the primates to reduce the viral RNA infection levels to very low levels creating a non progressor status for the primate. Then the SIV prototype vaccine for the GeoVax AIDS vaccine was administered. Six weeks following the final vaccinat...Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
...ual global sales expected to be around $350-400 million, based on current expectation of the competitive environment - Expected to be accretive for non GAAP earnings by the second half of 2010 - Acquisition to bring worldwide rights to FIRAZYR (Icatibant), a peptide based therapeutic for HAE which...New Australian Technology: Detecting Breast Cancer With Hair
...ld standard' for detecting the disease is mammography. According to Fermiscan's CEO, David Young, "The Fermiscan Test has the potential to provide a non invasive, fast and accurate addition to existing technologies for the detection of breast cancer in women of all ages. This test is not aimed at repla...As Summer Heats Up, New Survey Reveals Need for Effective Sweat Treatments
...feet and head, among other areas, and though not caused by heat, is aggravated by heat or anxiety. The International Hyperhidrosis Society (IHHS), a non profit organization dedicated to those who have the condition, commissioned Harris Interactive to conduct a survey among nearly 3,000 U.S. adults to f......velop lung cancer diagnostic tests, specifically, through identifying unique microRNA signatures that may predict risk of recurrence in stage I and II non Small Cell Lung Cancer (NSCLC) patients, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securi...
...for Stage IV disease is six months. Treatment of melanoma depends on the stage of the disease with surgical resection being effective in less severe non metastatic forms of the disease. However, survival rates for later Stage III and IV patients are poor, reflecting the lack of any efficacious drugs fo...
... the identification and diagnosis of brain malignancies. 6. "MicroRNAs as a diagnostic tool for differentiating squamous cell lung cancer from other non small cell lung cancers" Lung cancer is the leading cause of cancer-related death among men and women. Of all lung cancer cases, 80% are non-small-cel...
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
...t, MACE at 30 days, the rate was 2.2 percent, consisting of two in-hospital non Q-wave myocardial infarctions (MIs). At six-month follow-up the MACE rate f...or CUSTOM III was 7.8 percent. There were zero deaths, zero Q-wave MIs, two non Q-wave MIs, or 2.2 percent, and five clinically driven target lesion revasc......ies that are used to create its human and animal therapeutic agents. The most advanced human product candidate for Bioniche is Urocidin(TM) to treat non muscle-invasive bladder cancer. Urocidin(TM) entered Phase III clinical development in late 2006 after receiving Fast Track status from the U.S. Food ...
Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2007 Financial Results
... 83,419 324,774 Total current liabilities 303,285 772,846 Accrued expenses and other liabilities, non current 53,880 - Total liabilities 357,165 772,846 Tot...Other TagsWhatsGamesGamesFollowFollowFollowFollowOther Contentscrossovercrossovercrossovercrossovercrossoverchromosomalchromosomalchromosomalchromosomalchromosomalchromosomaltomographytomographytomographytomographytomographytomographytomographyaxialaxialaxialcomputedcomputedcomputedcomputedcomputedcomputedcultureculturecultureculturecultureculturecultureculturecultureculture
GatewayAlumniLandweberUntanglingMapTeachWhatsMATCsHartfordOutpouringGamesPlexusWhiningCorporationsFollow
(Date:12/14/2009)... tool use as a defining feature of humans. That,s until ... with birds and an array of other mammals. Now, a ... , a Cell Press publication, adds an octopus to the ... study manages a behavioral trick that the researchers call stilt ... upright coconut shell "bowls," makes its eight arms rigid, and ...
(Date:12/13/2009)... how a popular class of drugs used to ... hidden components of chemical communication in the brain. ... illness, people with schizophrenia also struggle to sustain ... difficulties that interfere with their ability to hold ... a student in the medical scientist training program ...
(Date:12/11/2009)... PAAs consumer demand for premium fruit increases, growers ... to market. And to boost their bottom line, ... can increase fruit quality while reducing labor costs. ... growers to produce larger, healthier fruit, is among ... significant impact on fruit production overhead, and, ultimately, ...
Breaking Biology News(10 mins):Tool use in an invertebrate: The coconut-carrying octopus 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Horizontal string trimmer reduces labor costs, increases peach size 2iMedica Selected by NJ Physicians as Preferred EHR Vendor 49173 1iMedica Selected by NJ Physicians as Preferred EHR Vendor 49173 2Watson to Acquire Arrow Group 49171 1Watson to Acquire Arrow Group 49171 2Watson to Acquire Arrow Group 49171 3Watson to Acquire Arrow Group 49171 4Watson to Acquire Arrow Group 49171 5Watson to Acquire Arrow Group 49171 6Watson to Acquire Arrow Group 49171 7ANSi Answers When Awarded the Philadelphia Business Journals Prestigious 2009 South Jersey 25 Accolade 49169 1ANSi Answers When Awarded the Philadelphia Business Journals Prestigious 2009 South Jersey 25 Accolade 49169 2(Date:12/14/2009)... Helps Locate Breast Lesions Quickly and Accurately for Biopsy ... ... 14, 2009 -- Dilon Diagnostics announced today that the ... for its lesion-localization system for molecular imaging biopsy guidance. ... product, the Dilon 6800 Gamma Camera. The GammaLMc® (GL) system ...
(Date:12/14/2009)... Congress to Ensure Health Workforce Recommendations are ... -- Congressional leaders must ensure that health ... with sufficient authority to ensure implementation of ... according to Dr. Steven A Wartman, president ... Health Centers (AAHC). "With each step ...
(Date:12/14/2009)... Dec. 14 Josie Raper, a 29 year-old mother ... six months with the help of the Dr. Siegal,s COOKIE ... the Joy Fit Club segment on NBC,s Today Show. The ... Bauer, airs twice a month and salutes those who have ... 2007 and has kept it off for two years. ,, ...
(Date:12/14/2009)... asked to approve naming the women,s hospital -- located ... complex -- after Ted and Jane Von Voigtlander ... University of Michigan Health System has received a $15 ... Foundation, the largest gift ever made to the Health ... of a new women,s hospital. ,, The gift is ...
(Date:12/14/2009)... Half of urban teenage girls may acquire at ... within two years of becoming sexually active, according to ... study. , The study appears in the December ... Medicine . , The researchers followed 381 girls enrolled ... repeated infection with the organisms that cause chlamydia, gonorrhea ...
Breaking Medicine News(10 mins):Health News:Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA 2Health News:Health Reform Needs Enforceable National Workforce Strategy 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 2Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 3Health News:Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club 4Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 2Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 3Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 4Health News:University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health 5Health News:IU study: Half of urban teen girls acquire STIs within 2 years of first sexual activity 2[0] Dilon Diagnostics Gamma-Guided Localization System Cleared by FDA [0] Health Reform Needs Enforceable National Workforce Strategy[0] Size 24 to 6 in Just 6 Months: NBC's Today Show Celebrates Dr. Siegal's Cookie Diet Success Story on Joy Fit Club[0] University of Michigan Health System Receives $15 Million Gift, The Largest Ever for Women's Health[0] IU study: Half of urban teen girls acquire STIs within 2 years of first sexual activity
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |